Clay Thorp - 18 Aug 2021 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc

Role: Director
Signature: /s/ John P. Sharp, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 18 Aug 2021
Net transactions value: +$30,000
Form type: 4
Filing time: 18 Aug 2021, 18:07:19 UTC
Previous filing: 11 Jun 2021
Next filing: 06 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PHASQ	Common Stock	Purchase	$30,000	+10,000	+44%	$3.00^*	32,943	18 Aug 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.97 to $3.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding he number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.97 to $3.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding he number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.